SERUM CARCINOEMBRYONIC ANTIGEN LEVEL AS A PREDICTIVE MARKER FOR DISTANT METASTASIS IN NON-SMALL CELL LUNG CANCER

Year 2007, Volume: 4 Issue: 3, 107 - 114, 01.09.2007

Ahmet Ursavaş Mehmet Karadağ İlker Ercan Özlem Özkubat Selma Yeşilkaya Funda Coşkun R Oktay Gözü

Abstract

-

Keywords

-

SERUM CARCINOEMBRYONIC ANTIGEN LEVEL AS A PREDICTIVE MARKER FOR DISTANT METASTASIS IN NON-SMALL CELL LUNG CANCER

Abstract

Aim: Elevated serum CEA (S-CEA) levels are sometimes attributable to the production of CEA by malignant cells, and in turn, the antigen itself can enhance the metastatic potential of malignant cells. We investigated the predictive role of S-CEA level for distant metastasis in nonsmall cell lung cancer (NSCLC). Methods: Consecutive 116 NSCLC patients referred to our department were retrospectively investigated. S-CEA levels was compared according to age, gender, smoking habits, histological type, distant metastases and clinical disease stage in all patients. Results: There were no significant relationship between S-CEA level and age, gender and smoking habits. There was significant difference in S-CEA level between M0 and M1 patients (p

Keywords

CEA, lung cancer, distant metastases

References

• Klee GG, Go VLW. Carcinoembryonic antigen and its role in clinical practice. In Ghosh BC, Ghosh L eds.:Tumor markers and tumor-associated antigens: 1 st edition. NewYork: McGraw-Hill Book Company 1990;22-43
• Gold P, Freedman SO. Specific carcinoembriyonic antigens of human digestive system. J Exp Med 1965;122: 467-81
• Zamcheck N. The present status of CEA in diagnosis, prognosis, and evaluation of therapy. Cancer 1975;36:2460-8
• Sugarbaker PH. Role of carcinoembriyonic antigen assay in the management of cancer. Adv Immun Cancer Ther 1985;1: 167-93
• Rule AH, Straus E, Vandevoorde J, Janowitz HD. Tumor-associated (CEA) reacting antigen in patients with inflammatory bowel disease. N Eng J Med 1972;287:24-6
• Ford CHJ, Stokes HJ, Newman CE. Carcinoembryonic antigen and prognosis after radical surgery for lung cancer: immunocytochemical localization and serum levels. Br J Cancer 1981;44:145- 53
• Dent PB, McCulloch PB, Wesley-James O, et al. Measurement of carcinoembriyonic antigen in patients with bronchogenic carcinoma. Cancer 1978;42:1484-91
• Concannon JP, Dalbow MH, Hodgson SE, et al. Prognostic value of preoperative carcinoembryonic antigen (CEA) in patients with bronchogenic carcinoma. Cancer 1978;42:1477-83
• Icard P, Regnard JF, Essomba A, et al. Preoperative carcinoembryonic antigen level as prognostic indicator in resected primary lung cancer. Ann Thorac Surg 1994;58:811-4
• Rubins JB, Dunitz J, Rubins HB, et al. Serum carcinoembryonic antigen as an adjunt to preoperative staging of lung cancer. J Thorac Cardiovasc Surg 1998; 116:412-6
• Hostetter RI, Augustus LB, Mankarious R, et al. Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastases. J Natl Cancer Inst 1990;82: 380-5
• Tomita M, Matsuzaki Y, Edagawa M, et al. Prognostic significance of preoperative serum carcinoembryonic antigen level in lung adenocarcinoma but not squamous cell carcinoma. Ann Thorac Cardiovasc Surg 2004;10:76-80
• Bilgin S, Yılmaz A, Özdemir F, et al. Extrathoracic staging of non-small cell bronchogenic carcinoma: Relationship of the clinical evaluation to organ scans. Respirology 2002;7:57-61
• Pfister DG, Johnson DH, Azzoli CG, et al. American society of clinical oncology treatment of unresectabl non-small cell lung cancer guideline. Update 2003
• Mountain CF. Revision in the international system for staging lung cancer. Chest 1997;111:1710-7
• N.I.H. Carcinoembryonic antigen: Its role as a marker in the management of cancer. Br Med J 1981;282: 373-5
• The American Thoracic Society and The European Respiratory Society. Pretreatment evaluation of non-small cell lung cancer. Am J Respir Crit Care Med 1997;156:320-2
• Vincent RG, Chu TM, Fergen TB, Ostrander M. Carcinoembryonic antigen in 228 patients with carcinoma of the lung. Cancer 1975:36:2069-76
• Suzuki K, Nagai K, Yoshida J, et al. Prognostic factor in clinical stage I no- small cell lung cancer. Ann Thorac Surg 1999;87:927-32
• Diez M, Torres A, Maestro MI, et al. Prediction of survival and recurrence by serum and cystosolic levels of CEA, CA 125 and SCC antigen in resectabl non- small cell lung camcer. Br J Cancer 1996; 73:1248-54
• Cristofori B, Amio G, Mengozzi G, et al. Tumor markers kinetic malignant lung neoplasm. J Cardiovasc Surg (Torino) 1999;40:299-305
• Hirasawa Y, Kohno N, Yokoyama A, et al. Natural autoantibody to MUCI is a prognostic indicator for no-small cell lung cancer. Am J Respir Crit Care Med 2000;161:589-94
• Foa P, Fornier M, Miceli R, et al. Tumor markers CEA, NSE, SCC, TPA, CYFRA 21.1 in resectabl non-small cell lung cancer. Anticancer Res 1999;19:3613-18
• Pelletier MP, Edwardes MD, Michel RP, et al. Prognostic markers in resectabl non-small cell lung cancer: a multivariate analysis. Can J Surg 2001;44:180-8
• Alexander JC, Silverman NA, Chretien PB. Effect of age and cigarette smoking on carcinoembryonic antigen levels. JAMA 1976;235:1975-9
• Okada M, Nishio W, Sakamoto T, et al. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non- small cell lung carcinoma. Ann Thorac surg 2004;78:1004-10
• Salgia R, Harpole D, Herndon JE, et al. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res 2001;21:1241-6
• Niklinski J, Furman M, Laudanski J, et al. evaluation of carcinoembryonic antigen (CEA. and brain type creatine kinase (CK-BB. in serum from patients with carcinoma of the lung. Neoplasma 1991;38:129-35
• Ando S, Kimura H, Iwai N, et al. Optimal combination of seven tumor markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Res 2001; 21:3085-92
• Takamochi K, Nagai K, Suzuki K, et al. Clinical predictors of N2 disease in non- small cell lung cancer. Chest 2000;117: 1577-82
• Nonaka M, Kataoka D, Yamamoto S, et al. Pre-andpost-operative serum carcinoembryonic antigen in primary lung adenocarcinoma. Ann Thorac Cardiovasc Surg 2004;10:281-4
• Tomita M, Matsuzaki Y, Shimizu T, et al. Serum carcinoembryonic antigen level in pN1 non-small cell lung cancer patients. Anticancer Res 2005;25:3601-5
• Tomita M, Matsuzaki Y, Shimizu T, et al. Prognostic determinats for lung cancer patients with preoperative high serum carcinoembryonic antigen levels. Thorac Cardiovasc Surg 2005;53:300-4
• Okada M, Nishio W, Sakamoto T, et al. Prognostic significance of preoperative carcinoembryonic antigen in non-small cell lung cancer: Analysis of 1000 consecutive resections for clinical stage I disease. Ann Thorac Surg 2004;78:216- 21
• Sawabata N, Maeda H, Yokota S, et al. Preoperative serum carcinoembriyonic antigen levels in patients with pathologic stage IA nonsmall cell lung carcinoma. Subnormal levels as indicator of favorable prognosis. Cancer 2004;101: 803-9
• Stokes TC, Stevens JFS, Long P, et al. Preoperative carcinoembryonic antigen and survival after resection of lung cancer. Br J Dis Chest 1980;74:390-4
• Buccheri G, Ferrigno D. Identifying patients at risk of early postoperative recurrence of lung cancer: A new use of the old CEA test. Ann Thorac Surg 2003; 75:973-80
• Erturan S, Yaman M, Aydýn G, et al. The role of whole-body bone scanning and clinical factors in detecting bone metastases in patients with non-small cell lung cancer. Chest 2005;127:449-54 39. The Canadian Oncology Group. Investigating extrathoracic metastatic disease in patients with apparently operable lung cancer. Ann Thorac Surg 2001;71:425-34
• Hetzel M, Hetzel J, Coskun A, et al. Reliability of symptoms to determine use of bone scans to identfy bone metastases in lung cancer: prospective study. BMJ 2004;328:1051-2